ABCHECK S.R.O.

AB CHECK

The mark consists of letters AB and CHECK separated by an array of circles.;Pharmaceutical and veterinary preparations, in particular preparations containing or consisting of binding molecules, peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments, pharmaceutical and veterinary preparations comprising or consisting of nucleic acid sequences coding for these molecules for treating infectious, inflammatory and tumorigenic diseases; preparations for therapeutic purposes, in particular human medicine purposes, diagnostic purposes, therapy or diagnosis of infectious, inflammatory and tumorigenic diseases;Color is not claimed as a feature of the mark.;Chemicals, in particular biochemical preparations, reagents, laboratory reagents, binding molecules, peptide or antibody libraries or peptides or antibodies, recombinant antibodies, single-chain antibodies, diabodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, antibody fragments, Fab fragments, nucleic acid sequences coding for these molecules, all for scientific and industrial purposes and research purposes, for use in molecular biology, in particular for the identification and characterisation of molecules, in particular proteins, enzymes and nucleic acids;AB OR CHECK;Scientific and technological services and research projects for the preparation of peptide and antibody libraries, namely, chemical analysis; scientific and technological services and research projects for the identification and characterisation of binding molecules, namely in the field of antibody discovery, antibody research and antibody optimization in the nature of working on and evaluation of chemical analyses; scientific and technological services and research projects for the preparation, identification and characterisation of peptides and antibodies, namely, medical research in the field of antibody discovery, antibody research and antibody optimization; scientific and technological services and research projects for the preparation and identification of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for these molecules, namely in the field of antibody discovery, antibody research and antibody optimization, namely, scientific research in the field of antibodies; scientific and technological services and research projects in relation to antibody discovery, namely, medical research in the field of antibody research and drug design; scientific and technological services and research projects in relation to screening of natural, engineered and immunized libraries, namely, medical research in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to screening of antibody libraries, namely in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to phage display, phage panning and yeast display vectors, namely in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to next-generation yeast display and antibody selection process, namely in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors in the nature of research and development services in the field of antibodies; scientific and technological services in relation to drug discovery by high throughput screen and antibody delivery for therapeutic application, namely scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to batch-cloning and screening of natural, engineered and immunized libraries, namely scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to batch-cloning and screening of antibody libraries, namely scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to antibody development strategies, namely scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to the optimization, maturation and humanization of antibody drug candidates, namely in the field of antibody research and drug design; scientific and technological services and research projects in relation to multi-factor antibody optimization, namely scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity, developability, producibility, and human properties, namely scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to human and non-human lead antibody technology, namely scientific research in the field of antibody research and antibody optimization;